- Home
- UAN vs ETNB Comparison
UAN vs ETNB Comparison
Compare UAN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- ETNB
- Stock Information
- Founded
- UAN 2007
- ETNB 2018
- Country
- UAN United States
- ETNB United States
- Employees
- UAN N/A
- ETNB N/A
- Industry
- UAN Agricultural Chemicals
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- ETNB Health Care
- Exchange
- UAN Nasdaq
- ETNB Nasdaq
- Market Cap
- UAN 793.5M
- ETNB 773.7M
- IPO Year
- UAN 2011
- ETNB 2019
- Fundamental
- Price
- UAN $81.47
- ETNB $10.75
- Analyst Decision
- UAN
- ETNB Strong Buy
- Analyst Count
- UAN 0
- ETNB 9
- Target Price
- UAN N/A
- ETNB $31.43
- AVG Volume (30 Days)
- UAN 36.3K
- ETNB 3.5M
- Earning Date
- UAN 02-18-2025
- ETNB 02-27-2025
- Dividend Yield
- UAN 8.19%
- ETNB N/A
- EPS Growth
- UAN N/A
- ETNB N/A
- EPS
- UAN 4.97
- ETNB N/A
- Revenue
- UAN $527,388,000.00
- ETNB N/A
- Revenue This Year
- UAN N/A
- ETNB N/A
- Revenue Next Year
- UAN N/A
- ETNB N/A
- P/E Ratio
- UAN $16.26
- ETNB N/A
- Revenue Growth
- UAN N/A
- ETNB N/A
- 52 Week Low
- UAN $61.62
- ETNB $5.99
- 52 Week High
- UAN $88.94
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- UAN 57.61
- ETNB 74.66
- Support Level
- UAN $80.28
- ETNB $9.16
- Resistance Level
- UAN $83.76
- ETNB $9.90
- Average True Range (ATR)
- UAN 2.29
- ETNB 0.83
- MACD
- UAN -0.24
- ETNB 0.41
- Stochastic Oscillator
- UAN 29.49
- ETNB 82.37
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).